» Articles » PMID: 37895373

EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) and Other Patient-Reported Outcomes in the Assessment of Glandular Dysfunction in Primary Sjögren's Syndrome

Overview
Journal Life (Basel)
Specialty Biology
Date 2023 Oct 28
PMID 37895373
Authors
Affiliations
Soon will be listed here.
Abstract

The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI), and other patient-reported outcomes (PROs), such as the visual analog scale (VAS) for symptoms and EULAR sicca score (ESS), are used to assess the disease activity of primary Sjögren's syndrome (pSS). Recently, Clinical ESSDAI (ClinESSDAI) and Clinical Trials ESSDAI (ClinTrialsESSDAI) were developed for objective clinical disease activity indexes. However, the relationship of ClinESSDAI and ClinTrialsESSDAI with PROs as well as that between ESSPRI and other PROs and the objective parameters of glandular function in pSS have not been established. Herein, we investigated the correlation of ESSPRI and other PROs with the objective parameters of glandular function and the relationship of PROs with ClinESSDAI and ClinTrialsESSDAI in 66 patients with pSS. Correlations were calculated with Spearman's correlation coefficient. ClinTrialsESSDAI was correlated with ESSPRI, dryness (ESSPRI-Dryness), fatigue, and pain domains of ESSPRI, VAS for oral dryness (oral-VAS), and patient's global assessment. Although ESSPRI did not correlate with the objective parameters of glandular function, ESSPRI-Dryness, ESS, and oral- and ocular-VAS did. These results suggest that ESSPRI-Dryness, ESS, and VAS for symptoms, but not ESSPRI, reflect the glandular dysfunction and that ClinTrialsESSDAI correlates with PROs for dryness in pSS.

Citing Articles

Sjögren's Disease and Gastroesophageal Reflux Disease: What Is Their Evidence-Based Link?.

Mieliauskaite D, Kontenis V Medicina (Kaunas). 2024; 60(11).

PMID: 39597079 PMC: 11596513. DOI: 10.3390/medicina60111894.


G protein-coupled receptor kinase 2 as a novel therapeutic target for gland fibrosis of Sjögren's syndrome.

Fang R, Zhou Z, Chu R, Guan Q, He F, Ge M Acta Pharmacol Sin. 2024; 45(12):2611-2624.

PMID: 39054339 PMC: 11579508. DOI: 10.1038/s41401-024-01350-4.

References
1.
Park E, Ha Y, Kang E, Song Y, Scofield R, Lee Y . Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome. Rheumatology (Oxford). 2020; 60(6):2714-2724. DOI: 10.1093/rheumatology/keaa687. View

2.
Bowman S, Hamburger J, Richards A, Barry R, Rauz S . Patient-reported outcomes in primary Sjogren's syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort--Sicca Symptoms Inventory. Rheumatology (Oxford). 2008; 48(2):140-3. DOI: 10.1093/rheumatology/ken426. View

3.
Salaffi F, Carotti M, Iagnocco A, Luccioli F, Ramonda R, Sabatini E . Ultrasonography of salivary glands in primary Sjögren's syndrome: a comparison with contrast sialography and scintigraphy. Rheumatology (Oxford). 2008; 47(8):1244-9. DOI: 10.1093/rheumatology/ken222. View

4.
Cho H, Yoo J, Yun C, Kang E, Lee H, Hyon J . The EULAR Sjogren's syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjogren's syndrome patients: in comparison with non-Sjogren's sicca patients. Rheumatology (Oxford). 2013; 52(12):2208-17. DOI: 10.1093/rheumatology/ket270. View

5.
Min H, Kim S, Lee K, Jo J, So Y, Chung H . Correlation between salivary gland ultrasonography and scintigraphy in primary Sjögren's syndrome. Rheumatology (Oxford). 2021; 61(8):3414-3419. DOI: 10.1093/rheumatology/keab881. View